Actively Recruiting
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Led by AbbVie · Updated on 2025-03-05
280
Participants Needed
7
Research Sites
257 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. This study will assess the (long-term) effectiveness and safety of upadacitinib in real-world clinical practice in adult participants with moderate to severe ulcerative colitis (UC) and crohn's disease (CD). Upadacitinib is an approved drug for treating ulcerative colitis (UC) and Crohn's disease (CD). Approximately 280 participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 8 sites across Belgium. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
CONDITIONS
Official Title
Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of moderate to severe Crohn's disease or ulcerative colitis
- Started upadacitinib treatment at least 12 months before joining the study, including those who stopped or switched treatments
- Starting commercially available upadacitinib as part of routine clinical care decided by their doctor before joining the study
- Prescribed upadacitinib according to approved local label and treatment guidelines
You will not qualify if you...
- Previously used upadacitinib in a clinical trial or early access program
- Currently participating in interventional research studies (except non-interventional ones)
- Having a stoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Imelda Ziekenhuis /ID# 268631
Bonheiden, Antwerpen, Belgium, 2820
Actively Recruiting
2
Universite Libre de Bruxelles - Hopital Erasme /ID# 268632
Anderlecht, Brussels Capital, Belgium, 1070
Actively Recruiting
3
CHU de Liège /ID# 267209
Liège, Liege, Belgium, 4000
Actively Recruiting
4
UZ Gent /ID# 268630
Ghent, Oost-Vlaanderen, Belgium, 9000
Actively Recruiting
5
Vitaz /Id# 268637
Sint-Niklaas, Oost-Vlaanderen, Belgium, 9100
Actively Recruiting
6
AZ Groeninge /ID# 268638
Kortrijk, West-Vlaanderen, Belgium, 8500
Actively Recruiting
7
Groupe Sante CHC - Clinique du MontLegia /ID# 268662
Liège, Belgium, 4000
Actively Recruiting
Research Team
L
Liesbeth Ghys
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here